Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 3/2017

01-06-2017 | Review

Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1

Authors: Rohit Sharma, Rohini Sharma, Tejinder Pal Khaket, Chanchala Dutta, Bornisha Chakraborty, Tapan Kumar Mukherjee

Published in: Cellular Oncology | Issue 3/2017

Login to get access

Abstract

Background

Breast cancer is a notable cause of cancer-related death in women worldwide. Metastasis to distant organs is responsible for ~90% of this death. Breast cells convert to malignant cancer cells after acquiring the capacity of invasion/intravasation into surrounding tissues and, finally, extravasation/metastasis to distant organs (i.e., lymph nodes, lungs, bone, brain). Metastasis to distant organs depends on interactions between disseminated tumor cells (DTCs) and the endothelium of blood vessels present in the tumor microenvironment. Among several known endothelial adhesion molecules, vascular cell adhesion molecule-1 (VCAM-1) has been found to be involved in this process. It has been shown that VCAM-1 is aberrantly expressed in breast cancer cells and that it can bind to its natural ligand α4β1integrin, also denoted as very late antigen 4 (VLA-4). This binding appears to be responsible for the metastasis of breast cancer cells to lung, bone and brain. The α4β1 integrin - VCAM-1 interaction thus represents a potential therapeutic target for metastatic breast cancer cells. The development of inhibitors of this interaction may be instrumental for the clinical management of breast cancer patients.

Conclusions

This study focuses on recent progress on the role of VCAM-1, an important glycoprotein belonging to the immunoglobulin (Ig) superfamily of cell surface adhesion molecules in breast cancer angiogenesis, survival and metastasis. Targeting VCAM-1, expressed on the surface of breast cancer cells, and/or its specific ligand VLA-4/α4β1 integrin, expressed on cells at the site of metastasis, may be a useful strategy to reduce breast cancer cell invasion and metastasis. Various approaches to therapeutically target VCAM-1 and VLA-4 are also discussed.
Literature
1.
M. Bendre, D. Gaddy, R.W. Nicholas, L.J. Suva, Breast cancer metastasis to bone: It is not all about PTHrP. Clin Orthop Relat Res 415, S39–S45 (2003)CrossRef
2.
D. Wolczyk, M. Zaremba-Czogalla, A. Hryniewicz-Jankowska, R. Tabola, K. Grabowski, A.F. Sikorski, K. Augoff, TNF-α promotes breast cancer cell migration and enhances the concentration of membrane-associated proteases in lipid rafts. Cell Oncol 39, 353–363 (2016)
3.
J.H. Howard, K.I. Bland, Current management and treatment strategies for breast cancer. Curr Opin Obstet Gynecol 24, 44–48 (2012)CrossRefPubMed
4.
E. Robles-Escajeda, U. Das, N.M. Ortega, K. Parra, G. Francia, J.R. Dimmock, A. Varela-Ramirez, R.J. Aguilera, A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell Oncol 39, 265–277 (2016)
5.
D. E. Berardi, C. Flumian, P. B. Campodonico, A. J Urtreger, M. I. Diaz Bessone, A. N. Motter, E. D. Bal de Kier Joffe, E. F. Farias, L. B. Todaro, Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid. Cell Oncol 38, 289–305 (2015)
6.
D. Alexiou, A.J. Karayiannakis, K.N. Syrigos, A. Zbar, A. Kremmyda, I. Bramis, C. Tsigris, Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: Correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer 37, 2392–2397 (2001)CrossRefPubMed
7.
Y.B. Ding, G.Y. Chen, J.G. Xia, X.W. Zang, H.Y. Yang, L. Yang, Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World J Gastroenterol 9, 1409–1414 (2003)CrossRefPubMedPubMedCentral
8.
B. Hemmerlein, J. Scherbening, A. Kugler, H.J. Radzun, Expression of VCAM-1, ICAM-1. E- and P-selectin and tumour-associated macrophages in renal cell carcinoma Histopathology 37, 78–83 (2000)
9.
L.P. Ruco, P.A. de Laat, C. Matteucci, S. Bernasconi, F.M. Sciacca, T.H. van der Kwast, H.C. Hoogsteden, S. Uccini, A. Mantovani, M.A. Versnel, Expression of ICAM-1 and VCAM-1 in human malignant mesothelioma. J Pathol 179, 266–271 (1996)CrossRefPubMed
10.
J. Huang, J. Zhang, H. Li, Z. Lu, W. Shan, I. Mercado-Uribe, J. Liu, VCAM1 expression correlated with tumorigenesis and poor prognosis, in high grade serous ovarian cancer. Am J Transl Res 5, 336–346 (2013)PubMedPubMedCentral
11.
Y. Okugawa, C. Miki, Y. Toiyama, Y. Koike, T. Yokoe, S. Saigusa, K. Tanaka, Y. Inoue, M. Kusunoki, Soluble VCAM-1 and its relation to disease progression in colorectal carcinoma. Exp Ther Med 1, 463–469 (2010)
12.
M. van Oosten, E. van de Bilt, H.E. de Vries, T.J. van Berkel, J. Kuiper, Vascular adhesion molecule-1 and intercellular adhesion molecule-1 expression on rat liver cells after lipopolysaccharide administration in vivo. Hepatology 22, 1538–1546 (1995)CrossRefPubMed
13.
D. Feuerbach, J.H. Feyen, Expression of the cell-adhesion molecule VCAM-1 by stromal cells is necessary for osteoclastogenesis. FEBS Lett 402, 21–24 (1997)CrossRefPubMed
14.
A. C. Stanley, J. E. Dalton, S. H. Rossotti, K. P. MacDonald, Y. Zhou, F. Rivera, W. A., Schroder, A. Maroof, G. R. Hil, P. M. Kaye, C. R. Engwerda, VCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasis. PLoS Pathol 4, e1000158 (2008)
15.
A.C. Van Dinther-Janssen, E. Horst, G. Koopman, W. Newmann, R.J. Scheper, C.J. Meijer, S.T. Pals, The VLA-4/VCAM-1 pathway is involved in lymphocyte adhesion to endothelium in rheumatoid synovium. J Immunol 147, 4207–4210 (1991)PubMed
16.
L. Devine, S.L. Lightman, J. Greenwood, Role of LFA-1, ICAM-1, VLA-4 and VCAM-1 in lymphocyte migration across retinal pigment epithelial monolayers in vitro. Immunology 88, 456–462 (1996)CrossRefPubMedPubMedCentral
17.
I. Mitroulis, V.I. Alexaki, I. Kourtzelis, A. Ziogas, G. Hajishengallis, T. Chavakis, Leukocyte integrins: Role in leukocyte recruitment and as therapeutic targets in inflammatory disease. Pharmacol Ther 147, 123–135 (2015)CrossRefPubMed
18.
Y. Takada, M. J. Elices, C. Crouse, M. E. Hemler, The primary structure of the alpha 4 subunit of VLA-4: homology to other integrins and a possible cell-cell adhesion function. EMBO J 8, 1361–1368 (1989)
19.
W.S. Argraves, S. Suzuki, H. Arai, K. Thompso, M.D. Pierschbacher, E. Ruoslahti, Amino acid sequence of the human fibronectin receptor. J Cell Biol 105, 1183–1190 (1987)CrossRefPubMed
20.
R. H. Vonderheide, T. F. Tedder, Springer T. A., Staunton D. E., Residues within a conserved amino acid motif of domains 1 and 4 of VCAM-1 are required for binding to VLA-4. J Cell Biol 125, 215–222 (1994)
21.
R.H. Vonderheide, T.A. Springer, Lymphocyte adhesion through very late antigen 4: Evidence for a novel binding site in the alternatively spliced domain of vascular cell adhesion molecule 1 and an additional alpha 4 integrin counter-receptor on stimulated endothelium. J Exp Med 175, 1433–1442 (1992)CrossRefPubMed
22.
T. Tatsumi, C. Shimazaki, H. Goto, S. Araki, Y. Sudo, N. Yamagata, E. Ashihara, T. Inaba, N. Fujita, M. Nakagawa, Expression of adhesion molecules on myeloma cells. Jpn J Cancer Res 87, 837–842 (1996)CrossRefPubMed
23.
B.S. Bochner, F.W. Luscinskas, M.A. Gimbrone, W. Newman, S.A. Sterbinsky, C.P. Derse-Anthony, D. Klunk, R.P. Schleimer, Adhesion of human basophils, eosinophils, and neutrophils to interleukin 1-activated human vascular endothelial cells: Contributions of endothelial cell adhesion molecules. J Exp Med 173, 1553–1557 (1991)CrossRefPubMed
24.
X. Zhang, S.E. Craig, H. Kirby, M.J. Humphries, V.T. Moy, Molecular basis for the dynamic strength of the integrin alpha4beta1/VCAM-1 interaction. Biophys J 87, 3470–3478 (2004)CrossRefPubMedPubMedCentral
25.
R.R. Langley, I.J. Fidler, The seed and soil hypothesis revisited--the role of tumor-stroma interactions in metastasis to different organs. Int J Cancer 128, 2527–2535 (2011)CrossRefPubMedPubMedCentral
26.
R. Paduch, The role of lymphangiogenesis and angiogenesis in tumor metastasis. Cell Oncol 39(397–410) (2016)
27.
J. Fukushi, M. Ono, W. Morikawa, Y. Iwamoto, M. Kuwano, The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. J Immunol 165, 2818–2823 (2000)CrossRefPubMed
28.
S. Karabulut, F. Tas, D. Tastekin, M. Karabulut, C.T. Yasasever, R. Ciftci, M. Güveli, M. Fayda, S. Vatansever, M. Serilmez, R. Disci, A. Aydıner, The diagnostic, predictive, and prognostic role of serum epithelial cell adhesion molecule (EpCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in breast cancer. Tumour Biol 35, 8849–8860 (2014)CrossRefPubMed
29.
G.J. Byrne, A. Ghella, J. Iddon, A.D. Blann, V. Venizelos, S. Kumar, A. Howell, N.J. Bundred, Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis. J Nat Cancer Inst 92, 1329–1336 (2000)CrossRefPubMed
30.
P. Tesarova, J. Kvasnicka, A. Umlaufova, J. Homolkova, M. Kalousova, V. Tesar, Soluble adhesion molecules in female patients with breast carcinoma. CasLekCesk 142, 292–299 (2003)
31.
H.C. Silva, F. Garcao, E.C. Coutinho, C.F. De Oliveira, F.J. Regateiro, Soluble VCAM-1 and E-selectin in breast cancer: Relationship with staging and with the detection of circulating cancer cells. Neoplasma 53, 538–543 (2006)PubMed
32.
Y. Maimaiti, C. Wang, M. Mushajiang, J. Tan, B. Huang, J. Zhou, T. Huang, Overexpression of VCAM-1 is correlated with poor survival of patients with breast cancer. Int J Clin Exp Pathol 9, 7451–7457 (2016)
33.
B.G. Susinia, C.J. Avraamidesa, J.S. Desgroselliera, M.C. Schmida, P. Fouberta, L.G. Elliesb, A.M. Lowya, S.L. Blaira, S.R. Vandenbergb, B. Datnowb, H.Y. Wang, D.A. Chereshb, J. Varner, PI3Kα activates integrin α4β1 to establish a metastatic niche in lymph nodes. Proc Natl Acad Sci U S A 110, 9042–9047 (2013)CrossRef
34.
A.J. Minn, G.P. Gupta, P.M. Siegel, P.D. Bos, W. Shu, D.D. Giri, A. Viale, A.B. Olshen, W.L. Gerald, J. Massague, Genes that mediate breast cancer metastasis to lung. Nature 436, 518–524 (2005)CrossRefPubMedPubMedCentral
35.
Q. Chen, X.H. Zhang, J. Massague, Macrophage binding to receptor VCAM-1 transmits survival signals in breast cancer cells that invade the lungs. Cancer Cell 20, 538–549 (2011)CrossRefPubMedPubMedCentral
36.
37.
O. Barreiro, M. Yanez-Mo, J.M. Serrador, M.C. Montoya, M. Vicente-Manzanares, R. Tejedor, H. Furthmayr, F. Sanchez-Madrid, Dynamic interaction of VCAM-1 and ICAM-1 with moesin and ezrin in a novel endothelial docking structure for adherent leukocytes. J Cell Biol 157, 1233–1245 (2002)CrossRefPubMedPubMedCentral
38.
X. Wang, Y. Wei, S. Yuan, G. Liu, Y. Lu, J. Zhang, W. Wang, Potential anticancer activity of tanshinone IIA against human breast cancer. Int J Cancer 116, 799–807 (2005)CrossRefPubMed
39.
D.M.O. Hanlon, H. Fitzsimons, J. Lynch, S. Tormey, C. Malone, H.F. Given, Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer 38, 2252–2257 (2002)CrossRef
40.
Y. Zheng, W. Yang, K. Aldape, J. He, Z. Lu, Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. J Biol Chem 288, 31488–31495 (2013)CrossRefPubMedPubMedCentral
41.
C. Gialeli, M. Viola, D. Barbouri, D. Kletsas, A. Passi, N.K. Karamanos, Dynamic interplay between breast cancer cells and normal endothelium mediates the expression of matrix macromolecules, proteasome activity and functional properties of endothelial cells. Biochim Biophys Acta 1840, 2549–2559 (2014)CrossRefPubMed
42.
H. Jin, S.Y. Eun, J.S. Lee, S.W. Park, J.H. Lee, K.C. Chang, H.J. Kim, P2Y2 receptor activation by nucleotides released from highly metastatic breast cancer cells increases tumor growth and invasion via crosstalk with endothelial cells. Breast Cancer Res 16, R77 (2014)CrossRefPubMedPubMedCentral
43.
C. Chen, D.B. Khismatullin, Lipopolysaccharide induces the interactions of breast cancer and endothelial cells via activated monocytes. Cancer Lett 345, 75–84 (2014)CrossRefPubMed
44.
L.A. Flores-Lopez, M.G. Martinez-Hernandez, R. Viedma-Rodríguez, M. Diaz-Flores, L.A. Baiza-Gutman, High glucose and insulin enhance uPA expression. ROS formation and invasiveness in breast cancer-derived cells. Cell Oncol 39, 365–378 (2016)
45.
X. Huang, D. He, J. Ming, Y. He, C. Zhou, H. Ren, X. He, C. Wang, J. Jin, L. Ji, B. Willard, B. Pan, L. Zheng, High density lipoprotein of patients with breast cancer complicated with type 2 diabetes mellitus promotes cancer cells adhesion to vascular endothelium via ICAM-1 and VCAM-1 upregulation. Breast Cancer Res Treat 155, 441–455 (2016)CrossRefPubMed
46.
A.J. Minn, G.P. Gupta, D. Padua, P. Bos, D.X. Nguyen, D. Nuyten, B. Kreike, Y. Zhang, Y. Wang, H. Ishwaran, J.A. Foekens, M. van de Vijver, J. Massague, Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A 104, 6740–6745 (2007)CrossRefPubMedPubMedCentral
47.
M.F. Lipscomb, D.E. Bice, C.R. Lyons, M.R. Schuyler, D. Wilkes, The regulation of pulmonary immunity Adv. Immunol 59, 369–455 (1995)
48.
M.Y. Kim, T. Oskarsson, S. Acharyya, D.X. Nguyen, X.H. Zhang, L. Norton, J. Massague, Tumor self-seeding by circulating cancer cells. Cell 139, 1315–1326 (2009)CrossRefPubMedPubMedCentral
49.
Y. Kang, W. He, S. Tulley, G.P. Gupta, I. Serganova, C.R. Chen, K. Manova-Todorova, R. Blasberg, W.L. Gerald, J. Massague, Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci USA 102, 13909–13914 (2005)CrossRefPubMedPubMedCentral
50.
Y. Kang, P.M. Siegel, W. Shu, M. Drobnjak, S.M. Kakonen, C. Cordon-Cardo, T.A. Guise, J.A. Massague, Multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3, 537–549 (2003)CrossRefPubMed
51.
X. Lu, E. Mu, Y. Wei, S. Riethdorf, Q. Yang, M. Yuan, J. Yan, Y. Hua, B.J. Tiede, X. Lu, B.G. Haffty, K. Pantel, J. Massague, Y. Kang, VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell 20, 701–714 (2011)CrossRefPubMedPubMedCentral
52.
B.K. Park, H. Zhang, Q. Zeng, J. Dai, E.T. Keller, T. Giordano, K. Gu, V. Shah, L. Pei, R.J. Zarbo, L. McCauley, S. Shi, S. Chen, C.Y. Wang, NF-[kappa]B in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13, 62–69 (2007)CrossRefPubMed
53.
I. Pecheur, O. Peyruchaud, C.M. Serre, J. Guglielmi, C. Voland, F. Bourre, C. Margue, M. Cohen-Solal, A. Buffet, N. Kieffer, P. Clezardin, Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. FASEB J 16, 1266–1268 (2002)PubMed
54.
S. Serres, M.S. Soto, A. Hamilton, M.A. McAteer, W.S. Carbonell, M.D. Robson, O. Ansorge, A. Khrapitchev, C. Bristow, L. Balathasan, T. Weissensteiner, D.C. Anthony, R.P. Choudhury, R.J. Muschel, N.R. Sibson, Molecular MRI enables early and sensitive detection of brain metastases. Proc Natl Acad Sci USA 109, 6674–6679 (2012)CrossRefPubMedPubMedCentral
55.
M.S. Soto, S. Serres, D.C. Anthony, N.R. Sibson, Functional role of endothelial adhesion molecules in the early stages of brain metastasis. Neuro-Oncology 16, 540–551 (2014)CrossRefPubMed
56.
T. Yoneda, P.J. Williams, T. Hiraga, M. Niewolna, R. Nishimura, A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J Bone Miner Res 16, 1486–1495 (2001)CrossRefPubMed
57.
58.
P.C. Wang, C.C. Weng, Y.S. Hou, S.F. Jian, K.T. Fang, M.F. Hou, K.H. Cheng, Activation of VCAM-1 and its associated molecule CD44 leads to increased malignant potential of breast cancer cells. Int J Mol Sci 15, 3560–3579 (2014)CrossRefPubMedPubMedCentral
59.
C.Y. Lee, H.F. Sher, H.W. Chen, C.C. Liu, C.H. Chen, C.S. Lin, P.C. Yang, H.S. Tsay, J.J. Chen, Anticancer effects of tanshinone I in human non-small cell lung cancer. Mol Cancer Ther 7, 3527–3538 (2008)CrossRefPubMed
60.
I.T. Nizamutdinova, G.W. Lee, J.S. Lee, M.K. Cho, K.H. Son, S.J. Jeon, S.S. Kang, Y.S. Kim, J.H. Lee, H.G. Seo, K.C. Chang, H.J. Kim, Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis 29, 1885–1892 (2008)CrossRefPubMed
61.
V. Nicolin, G. Fancellu, R. Valentini, Effect of tanshinone II on cell growth of breast cancer cell line type MCF-7 and MD-MB-231. Ital J Anat Embryol 119, 38–43 (2014)PubMed
62.
C. Lin, L. Wang, H. Wang, L. Yang, H. Guo, X. Wang, Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways. J Cell Biochem 114, 2061–2070 (2013)CrossRefPubMed
63.
H. Jin, W.S. Lee, J.W. Yun, J.H. Jung, S.M. Yi, H.J. Kim, Y.H. Choi, G. Kim, J.M. Jung, C.H. Ryu, S.C. Shin, S.C. Hong, Flavonoids from Citrus Unshiu Marc inhibit cancer cell adhesion to endothelial cells by selective inhibition of VCAM-1. Oncol Rep 30, 2336–2342 (2013)PubMed
64.
O.J. Leger, T.A. Yednock, L. Tanner, H.C. Horner, D.K. Hines, S. Keen, J. Saldanha, S.T. Jones, L.C. Fritz, M.M. Bendig, Humanization of a mouse antibody against human alpha-4 integrin: A potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 8, 3–16 (1997)PubMed
65.
K. Podar, A. Zimmerhackl, M. Fulciniti, G. Tonon, U. Hainz, Y.T. Tai, S. Vallet, N. Halama, D. Jager, D.L. Olson, M. Sattler, D. Chauhan, K.C. Anderson, The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: Therapeutic implications. Br J Haematol 155, 438–448 (2011)CrossRefPubMed
66.
C. Kibler, F. Schermutzki, H.D. Waller, R. Timpl, C.A. Muller, G. Klein, Adhesive interactions of human multiple myeloma cell lines with different extracellular matrix molecules. Cell Adhes Commun 5, 307–323 (1998)CrossRefPubMed
67.
T. Michigami, N. Shimizu, P.J. Williams, M. Niewolna, S.L. Dallas, G.R. Mundy, T. Yoneda, Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha(4)beta(1)-integrin enhances production of osteoclast-stimulating activity. Blood 96, 1953–1960 (2000)PubMed
68.
M.T. de la Fuente, B. Casanova, M. Garcia-Gila, A. Silva, A. Garcia-Pardo, Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: Correlation with Bcl-2 and Bax. Leukemia 13, 266–274 (1999)CrossRefPubMed
69.
M. Watanabe, N. Yoshimura, S. Motoya, K. Tominaga, R. Iwakiri, K. Watanabe, T. Hibi, AJM300, an oral a4 integrin antagonist, for active ulcerative colitis: A multicenter, randomized, double-blind, placebo-controlled phase 2a study. Gastrointest Endosc 79, AB401 (2014)CrossRef
70.
T. Sugiura, S. Kageyama, A. Andou, T. Miyazawa, C. Ejima, A. Nakayama, T. Dohi, H. Eda, Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis 7, e533–e542 (2013)CrossRefPubMed
71.
M. Takazoe, M. Watanabe, T. Kawaguchi, T. Matumoto, N. Oshitani, N. Hiwatashi, T. Hibi, S1066 Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 136, A-181 (2009)
72.
Biogen Idec Clinical Trials gov National Library of Medicine (US), Bethesda (MD):2008–2011 Study of Natalizumab in Relapsed/Refractory Multiple Myeloma. Available from: http://​clinicaltrialsgo​v/​show/​NCT00675428 NLM Identifier: NCT00675428
73.
C.G. Lee, H.W. Lee, B. Kim, D.K. Rhee, D. Pyo, Allicin inhibits invasion and migration of breast cancer cells through the suppression of VCAM-1: Regulation of association between p65 and ER-α. J Functional Foods 15, 172–185 (2015)CrossRef
74.
H. Cao, Z. Zhang, S. Zhao, X. He, H. Yu, Q. Yin, Z. Zhang, W. Gu, L. Chen, Y. Li, Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression. J Control Release 205, 162–171 (2015)CrossRefPubMed
75.
N. Zhang, C. Chittasupho, C. Duangrat, T.J. Siahaan, C. Berkland, PLGA nanoparticle-peptide conjugate effectively targets intercellular cell-adhesion molecule-1. Bioconjug Chem 19, 145–152 (2008)CrossRefPubMed
76.
S. Gosk, T. Moos, C. Gottstein, G. Bendas, VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochimica Biophysica Acta-Biomembranes 1778, 854–863 (2008)CrossRef
77.
D.I. Kang, S. Lee, J.T. Lee, B.J. Sung, J.Y. Yoon, J.K. Kim, J. Chung, S.J. Lim, Preparation and in vitro evaluation of anti-VCAM-1-Fab'-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib. J Microencapsul 28, 220–227 (2011)CrossRefPubMed
78.
M. Voinea, I. Manduteanu, E. Dragomir, M. Capraru, M. Simionescu, Immunoliposomes directed toward VCAM-1 interact specifically with activated endothelial cells--a potential tool for specific drug delivery. Pharm Res 22, 1906–1917 (2005)CrossRefPubMed
Metadata
Title
Breast cancer metastasis: Putative therapeutic role of vascular cell adhesion molecule-1
Authors
Rohit Sharma
Rohini Sharma
Tejinder Pal Khaket
Chanchala Dutta
Bornisha Chakraborty
Tapan Kumar Mukherjee
Publication date
01-06-2017
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 3/2017
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-017-0324-x

Other articles of this Issue 3/2017

Cellular Oncology 3/2017 Go to the issue

Original Paper

Dual treatment with shikonin and temozolomide reduces glioblastoma tumor growth, migration and glial-to-mesenchymal transition

Original Paper

Integrative transcriptome analysis of liver cancer profiles identifies upstream regulators and clinical significance of ACSM3 gene expression

Original Paper

Silymarin and its active component silibinin act as novel therapeutic alternatives for salivary gland cancer by targeting the ERK1/2-Bim signaling cascade

Report

Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome

Original Paper

Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition

Original Paper

Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits